JPWO2020052631A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020052631A5 JPWO2020052631A5 JP2021513827A JP2021513827A JPWO2020052631A5 JP WO2020052631 A5 JPWO2020052631 A5 JP WO2020052631A5 JP 2021513827 A JP2021513827 A JP 2021513827A JP 2021513827 A JP2021513827 A JP 2021513827A JP WO2020052631 A5 JPWO2020052631 A5 JP WO2020052631A5
- Authority
- JP
- Japan
- Prior art keywords
- triazolo
- methyl
- amino
- alkyl
- pyrimidin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- -1 cyano, hydroxyl Chemical group 0.000 claims 147
- 125000000217 alkyl group Chemical group 0.000 claims 85
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 34
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 30
- 150000001875 compounds Chemical class 0.000 claims 26
- XSQUKJJJFZCRTK-UHFFFAOYSA-N urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims 24
- 125000004452 carbocyclyl group Chemical group 0.000 claims 23
- 125000000623 heterocyclic group Chemical group 0.000 claims 22
- 229910052736 halogen Inorganic materials 0.000 claims 19
- 150000002367 halogens Chemical group 0.000 claims 19
- 125000004642 (C1-C12) alkoxy group Chemical group 0.000 claims 18
- 125000004438 haloalkoxy group Chemical group 0.000 claims 15
- 125000004641 (C1-C12) haloalkyl group Chemical group 0.000 claims 14
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 13
- KXDHJXZQYSOELW-UHFFFAOYSA-M carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims 12
- 239000004202 carbamide Substances 0.000 claims 12
- 125000005236 alkanoylamino group Chemical group 0.000 claims 10
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- 125000002947 alkylene group Chemical group 0.000 claims 5
- 102000004965 antibodies Human genes 0.000 claims 5
- 108090001123 antibodies Proteins 0.000 claims 5
- 229910052760 oxygen Inorganic materials 0.000 claims 5
- 102000009346 Adenosine receptors Human genes 0.000 claims 4
- 108050000203 Adenosine receptors Proteins 0.000 claims 4
- 239000002246 antineoplastic agent Substances 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims 3
- 125000001153 fluoro group Chemical group F* 0.000 claims 3
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 claims 3
- 239000002955 immunomodulating agent Substances 0.000 claims 3
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 3
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical group [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 claims 3
- 125000002950 monocyclic group Chemical group 0.000 claims 3
- 125000004076 pyridyl group Chemical group 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 239000011780 sodium chloride Substances 0.000 claims 3
- 229910052717 sulfur Inorganic materials 0.000 claims 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 3
- OIRDTQYFTABQOQ-GAWUUDPSSA-N 9-β-D-XYLOFURANOSYL-ADENINE Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@H](O)[C@H]1O OIRDTQYFTABQOQ-GAWUUDPSSA-N 0.000 claims 2
- OIRDTQYFTABQOQ-SXVXDFOESA-N Adenosine Natural products Nc1ncnc2c1ncn2[C@@H]3O[C@@H](CO)[C@H](O)[C@@H]3O OIRDTQYFTABQOQ-SXVXDFOESA-N 0.000 claims 2
- 208000006673 Asthma Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 239000002126 C01EB10 - Adenosine Substances 0.000 claims 2
- 206010007556 Cardiac failure acute Diseases 0.000 claims 2
- 206010007558 Cardiac failure chronic Diseases 0.000 claims 2
- 206010008120 Cerebral ischaemia Diseases 0.000 claims 2
- 206010057668 Cognitive disease Diseases 0.000 claims 2
- 206010010099 Combined immunodeficiency Diseases 0.000 claims 2
- 206010015037 Epilepsy Diseases 0.000 claims 2
- 208000004361 Obstructive Lung Disease Diseases 0.000 claims 2
- 206010061536 Parkinson's disease Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000006265 Renal Cell Carcinoma Diseases 0.000 claims 2
- 241000580858 Simian-Human immunodeficiency virus Species 0.000 claims 2
- 208000006011 Stroke Diseases 0.000 claims 2
- 229960005305 adenosine Drugs 0.000 claims 2
- 201000006474 brain ischemia Diseases 0.000 claims 2
- 230000001684 chronic Effects 0.000 claims 2
- 201000002403 combined T cell and B cell immunodeficiency Diseases 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 125000005842 heteroatoms Chemical group 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 125000004435 hydrogen atoms Chemical class [H]* 0.000 claims 2
- 125000001841 imino group Chemical group [H]N=* 0.000 claims 2
- 201000005244 lung non-small cell carcinoma Diseases 0.000 claims 2
- 125000003566 oxetanyl group Chemical group 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims 2
- 125000005494 pyridonyl group Chemical group 0.000 claims 2
- 238000001959 radiotherapy Methods 0.000 claims 2
- ZROHGHOFXNOHSO-BNTLRKBRSA-L (1R,2R)-cyclohexane-1,2-diamine;oxalate;platinum(2+) Chemical compound [H][N]([C@@H]1CCCC[C@H]1[N]1([H])[H])([H])[Pt]11OC(=O)C(=O)O1 ZROHGHOFXNOHSO-BNTLRKBRSA-L 0.000 claims 1
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims 1
- FFNVQNRYTPFDDP-UHFFFAOYSA-N 2-cyanopyridine Chemical compound N#CC1=CC=CC=N1 FFNVQNRYTPFDDP-UHFFFAOYSA-N 0.000 claims 1
- AOJJSUZBOXZQNB-TZSSRYMLSA-N ADRIAMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 1
- 102100007290 CD274 Human genes 0.000 claims 1
- 101710012053 CD274 Proteins 0.000 claims 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N Docetaxel Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 1
- 229960004679 Doxorubicin Drugs 0.000 claims 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N Etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims 1
- 229960005420 Etoposide Drugs 0.000 claims 1
- HPXVMQGCIJGOCF-UHFFFAOYSA-N FC1=CC=C(C=C1)C1=C(C=2N(C(=N1)N)N=C(N=2)CC=1N=C(SC=1)C)C=1C=CC=2N(C=1)C=CN=2 Chemical compound FC1=CC=C(C=C1)C1=C(C=2N(C(=N1)N)N=C(N=2)CC=1N=C(SC=1)C)C=1C=CC=2N(C=1)C=CN=2 HPXVMQGCIJGOCF-UHFFFAOYSA-N 0.000 claims 1
- RCINICONZNJXQF-MZXODVADSA-N Intaxel Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 1
- 229960001156 Mitoxantrone Drugs 0.000 claims 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N Mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 claims 1
- LWYDAAASGGAOQH-UHFFFAOYSA-N NC1=NC(=C(C=2N1N=C(N=2)CC1=C(C=CC=C1F)F)C1=CC(=NC(=C1)C)C#N)C=1OC=CN=1 Chemical compound NC1=NC(=C(C=2N1N=C(N=2)CC1=C(C=CC=C1F)F)C1=CC(=NC(=C1)C)C#N)C=1OC=CN=1 LWYDAAASGGAOQH-UHFFFAOYSA-N 0.000 claims 1
- BJCXOFQLGPZNJF-UHFFFAOYSA-N NC1=NC(=C(C=2N1N=C(N=2)CC1=C(C=CC=C1F)F)C=1C=CC(N(C=1)C)=O)C1=NC=CC=C1 Chemical compound NC1=NC(=C(C=2N1N=C(N=2)CC1=C(C=CC=C1F)F)C=1C=CC(N(C=1)C)=O)C1=NC=CC=C1 BJCXOFQLGPZNJF-UHFFFAOYSA-N 0.000 claims 1
- FYGUOAMXRGGXGR-UHFFFAOYSA-N NC1=NC(=C(C=2N1N=C(N=2)CC1=C(C=CC=C1F)F)C=1C=CC(N(C=1)C)=O)C=1C=NC(=CC=1)C Chemical compound NC1=NC(=C(C=2N1N=C(N=2)CC1=C(C=CC=C1F)F)C=1C=CC(N(C=1)C)=O)C=1C=NC(=CC=1)C FYGUOAMXRGGXGR-UHFFFAOYSA-N 0.000 claims 1
- XGANDSJRULUAJD-UHFFFAOYSA-N NC1=NC(=C(C=2N1N=C(N=2)CC1=C(C=CC=C1F)F)C=1C=CC(N(C=1)C)=O)Cl Chemical compound NC1=NC(=C(C=2N1N=C(N=2)CC1=C(C=CC=C1F)F)C=1C=CC(N(C=1)C)=O)Cl XGANDSJRULUAJD-UHFFFAOYSA-N 0.000 claims 1
- NOYVLVDEKLNKFK-UHFFFAOYSA-N NC1=NC(=C(C=2N1N=C(N=2)CC1=C(C=CC=C1F)F)C=1C=CC(N(C=1)C)=O)N1N=CC=N1 Chemical compound NC1=NC(=C(C=2N1N=C(N=2)CC1=C(C=CC=C1F)F)C=1C=CC(N(C=1)C)=O)N1N=CC=N1 NOYVLVDEKLNKFK-UHFFFAOYSA-N 0.000 claims 1
- OGILCXDJHLQZTN-UHFFFAOYSA-N NC1=NC(=C(C=2N1N=C(N=2)CC1=CC=CC(=N1)N)C=1C=CC=2N(C=1)C=CN=2)C1=CC=C(C=C1)F Chemical compound NC1=NC(=C(C=2N1N=C(N=2)CC1=CC=CC(=N1)N)C=1C=CC=2N(C=1)C=CN=2)C1=CC=C(C=C1)F OGILCXDJHLQZTN-UHFFFAOYSA-N 0.000 claims 1
- DRWXKQJJYFKKOA-UHFFFAOYSA-N NC1=NC(=C(C=2N1N=C(N=2)CC1=NC(=CC=C1)N)C=1C=CC(N(C=1)C)=O)C1=CC=C(C=C1)F Chemical compound NC1=NC(=C(C=2N1N=C(N=2)CC1=NC(=CC=C1)N)C=1C=CC(N(C=1)C)=O)C1=CC=C(C=C1)F DRWXKQJJYFKKOA-UHFFFAOYSA-N 0.000 claims 1
- UFJDURNDZGLRES-UHFFFAOYSA-N NC1=NC(=C(C=2N1N=C(N=2)CC1=NC=CC=C1F)C1=CN(C(C=C1)=O)C)C1=CC=C(C#N)C=C1 Chemical compound NC1=NC(=C(C=2N1N=C(N=2)CC1=NC=CC=C1F)C1=CN(C(C=C1)=O)C)C1=CC=C(C#N)C=C1 UFJDURNDZGLRES-UHFFFAOYSA-N 0.000 claims 1
- YIDWZRRYJRXRPX-UHFFFAOYSA-N NC1=NC(=C(C=2N1N=C(N=2)CC1=NC=CC=C1F)C=1C=CC(N(C=1)C(C)C)=O)C1=CC=C(C=C1)F Chemical compound NC1=NC(=C(C=2N1N=C(N=2)CC1=NC=CC=C1F)C=1C=CC(N(C=1)C(C)C)=O)C1=CC=C(C=C1)F YIDWZRRYJRXRPX-UHFFFAOYSA-N 0.000 claims 1
- CUZJHUAIWPKQIM-UHFFFAOYSA-N NC1=NC(=C(C=2N1N=C(N=2)CC1=NC=CC=C1F)C=1C=CC(N(C=1)C)=O)C1=CC(=C(C=C1)F)F Chemical compound NC1=NC(=C(C=2N1N=C(N=2)CC1=NC=CC=C1F)C=1C=CC(N(C=1)C)=O)C1=CC(=C(C=C1)F)F CUZJHUAIWPKQIM-UHFFFAOYSA-N 0.000 claims 1
- ANVNFQJDCKBOSL-UHFFFAOYSA-N NC1=NC(=C(C=2N1N=C(N=2)CC1=NC=CC=C1F)C=1C=CC(N(C=1)C)=O)C=1OC=CN=1 Chemical compound NC1=NC(=C(C=2N1N=C(N=2)CC1=NC=CC=C1F)C=1C=CC(N(C=1)C)=O)C=1OC=CN=1 ANVNFQJDCKBOSL-UHFFFAOYSA-N 0.000 claims 1
- WWGWJTQBATTYLS-UHFFFAOYSA-N NC1=NC(=C(C=2N1N=C(N=2)CC1=NC=CC=C1F)C=1C=CC(N(C=1)C)=O)N1N=CC=C1 Chemical compound NC1=NC(=C(C=2N1N=C(N=2)CC1=NC=CC=C1F)C=1C=CC(N(C=1)C)=O)N1N=CC=C1 WWGWJTQBATTYLS-UHFFFAOYSA-N 0.000 claims 1
- BFFFIJSOBYMNPI-UHFFFAOYSA-N NC1=NC(=C(C=2N1N=C(N=2)CC1=NC=CC=C1F)C=1C=CC(N(C=1)CC)=O)C1=CC=C(C=C1)F Chemical compound NC1=NC(=C(C=2N1N=C(N=2)CC1=NC=CC=C1F)C=1C=CC(N(C=1)CC)=O)C1=CC=C(C=C1)F BFFFIJSOBYMNPI-UHFFFAOYSA-N 0.000 claims 1
- MGVORKOWNJZJCZ-SFHVURJKSA-N NC1=NC(=C(C=2N1N=C(N=2)CC1=NC=CC=C1F)C=1C=CC(N(C=1)[C@@H]1COCC1)=O)C1=CC=C(C=C1)F Chemical compound NC1=NC(=C(C=2N1N=C(N=2)CC1=NC=CC=C1F)C=1C=CC(N(C=1)[C@@H]1COCC1)=O)C1=CC=C(C=C1)F MGVORKOWNJZJCZ-SFHVURJKSA-N 0.000 claims 1
- IVLZUGWDYRIRPP-UHFFFAOYSA-N NC1=NC(=C(C=2N1N=C(N=2)CC1=NC=CC=C1OC(F)F)C=1C=CC(N(C=1)C)=O)C1=CC=C(C=C1)F Chemical compound NC1=NC(=C(C=2N1N=C(N=2)CC1=NC=CC=C1OC(F)F)C=1C=CC(N(C=1)C)=O)C1=CC=C(C=C1)F IVLZUGWDYRIRPP-UHFFFAOYSA-N 0.000 claims 1
- HNQYRYXKHXZOGM-UHFFFAOYSA-N NC1=NC(=C(C=2N1N=C(N=2)CC1=NC=CC=C1OC(F)F)C=1C=CC(N(C=1)C)=O)C=1OC=CN=1 Chemical compound NC1=NC(=C(C=2N1N=C(N=2)CC1=NC=CC=C1OC(F)F)C=1C=CC(N(C=1)C)=O)C=1OC=CN=1 HNQYRYXKHXZOGM-UHFFFAOYSA-N 0.000 claims 1
- FAFWPWMKYLQUHT-UHFFFAOYSA-N NC1=NC(=C(C=2N1N=C(N=2)CC=1N=CSC=1)C=1C=CC(N(C=1)C)=O)C1=CC=C(C=C1)F Chemical compound NC1=NC(=C(C=2N1N=C(N=2)CC=1N=CSC=1)C=1C=CC(N(C=1)C)=O)C1=CC=C(C=C1)F FAFWPWMKYLQUHT-UHFFFAOYSA-N 0.000 claims 1
- DFXFMJLXQWVGCL-UHFFFAOYSA-N NC1=NC(=C(C=2N1N=C(N=2)CC=1SC=CN=1)C=1C=CC(N(C=1)C)=O)C1=CC=C(C=C1)F Chemical compound NC1=NC(=C(C=2N1N=C(N=2)CC=1SC=CN=1)C=1C=CC(N(C=1)C)=O)C1=CC=C(C=C1)F DFXFMJLXQWVGCL-UHFFFAOYSA-N 0.000 claims 1
- 229960001592 Paclitaxel Drugs 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 229960004316 cisplatin Drugs 0.000 claims 1
- 238000002648 combination therapy Methods 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 229960003668 docetaxel Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000006005 fluoroethoxy group Chemical group 0.000 claims 1
- 238000009169 immunotherapy Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 229960001756 oxaliplatin Drugs 0.000 claims 1
- 229910052697 platinum Inorganic materials 0.000 claims 1
- 125000002098 pyridazinyl group Chemical group 0.000 claims 1
- UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical compound OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 claims 1
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 claims 1
- FVLAYJRLBLHIPV-UHFFFAOYSA-N pyrimidin-5-amine Chemical compound NC1=CN=CN=C1 FVLAYJRLBLHIPV-UHFFFAOYSA-N 0.000 claims 1
- 229930003347 taxol Natural products 0.000 claims 1
- LXZZYRPGZAFOLE-UHFFFAOYSA-L transplatin Chemical compound [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H] LXZZYRPGZAFOLE-UHFFFAOYSA-L 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2018105220 | 2018-09-12 | ||
| CNPCT/CN2018/105220 | 2018-09-12 | ||
| PCT/CN2019/105591 WO2020052631A1 (en) | 2018-09-12 | 2019-09-12 | Triazolo-pyrimidine compounds and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022500402A JP2022500402A (ja) | 2022-01-04 |
| JPWO2020052631A5 true JPWO2020052631A5 (ko) | 2022-09-05 |
Family
ID=69778192
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021513827A Pending JP2022500402A (ja) | 2018-09-12 | 2019-09-12 | トリアゾロ−ピリミジン化合物およびそれらの使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US10858365B2 (ko) |
| EP (1) | EP3849983A4 (ko) |
| JP (1) | JP2022500402A (ko) |
| KR (1) | KR20210075996A (ko) |
| CN (3) | CN111635408B (ko) |
| AR (1) | AR116315A1 (ko) |
| AU (1) | AU2019340767A1 (ko) |
| BR (1) | BR112021004774A2 (ko) |
| CA (1) | CA3111869A1 (ko) |
| MX (1) | MX2021002998A (ko) |
| TW (1) | TWI820209B (ko) |
| WO (1) | WO2020052631A1 (ko) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11066410B2 (en) * | 2017-03-24 | 2021-07-20 | 3100 Central Expressway Llc | Fused triazolo-pyrimidine compounds having useful pharmaceutical application |
| US11028058B2 (en) | 2017-07-18 | 2021-06-08 | Nuvation Bio Inc. | Heterocyclic compounds as adenosine antagonists |
| CN112384515A (zh) | 2018-02-27 | 2021-02-19 | 因赛特公司 | 作为a2a/a2b抑制剂的咪唑并嘧啶和三唑并嘧啶 |
| US11220510B2 (en) | 2018-04-09 | 2022-01-11 | Incyte Corporation | Pyrrole tricyclic compounds as A2A / A2B inhibitors |
| MA52940A (fr) | 2018-05-18 | 2021-04-28 | Incyte Corp | Dérivés de pyrimidine fusionnés utilisés en tant qu'inhibiteurs de a2a/a2b |
| EP3818063A1 (en) | 2018-07-05 | 2021-05-12 | Incyte Corporation | Fused pyrazine derivatives as a2a / a2b inhibitors |
| AR116315A1 (es) * | 2018-09-12 | 2021-04-21 | Dizal Jiangsu Pharmaceutical Co Ltd | Compuestos de triazolo-pirimidina y usos de los mismos |
| WO2020150674A1 (en) | 2019-01-18 | 2020-07-23 | Nuvation Bio Inc. | Heterocyclic compounds as adenosine antagonists |
| JP2022523473A (ja) | 2019-01-18 | 2022-04-25 | ニューベイション・バイオ・インコーポレイテッド | １，８－ナフチリジジノン化合物およびそれらの使用 |
| TWI829857B (zh) | 2019-01-29 | 2024-01-21 | 美商英塞特公司 | 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶 |
| CA3150766A1 (en) * | 2019-08-26 | 2021-03-04 | Incyte Corporation | Triazolopyrimidines as a2a / a2b inhibitors |
| WO2021156439A1 (en) | 2020-02-06 | 2021-08-12 | Astrazeneca Ab | Triazole compounds as adenosine receptor antagonists |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2284737C (en) * | 1997-03-24 | 2007-03-13 | Kyowa Hakko Kogyo Co., Ltd. | [1,2,4]triazolo[1,5-c]pyrimidine derivatives |
| JPWO2002079204A1 (ja) * | 2001-03-28 | 2004-07-22 | 協和醗酵工業株式会社 | ８−チアゾリル［１，２，４］トリアゾロ［１，５−ｃ］ピリミジン誘導体 |
| TW200300686A (en) * | 2001-11-30 | 2003-06-16 | Schering Corp | Adenosine A2a receptor antagonists |
| CA2500228A1 (en) * | 2002-09-24 | 2004-04-08 | Kyowa Hakko Kogyo Co., Ltd. | [1,2,4]-triazolo[1,5-c]pyrimidine derivative |
| US10399962B2 (en) * | 2017-01-20 | 2019-09-03 | Arcus Biosciences, Inc. | Azolopyrimidine for the treatment of cancer-related disorders |
| JP7111733B2 (ja) * | 2017-03-16 | 2022-08-02 | 江蘇恒瑞医薬股▲ふん▼有限公司 | ヘテロアリール［４，３－ｃ］ピリミジン－５－アミン誘導体、その製造方法、およびその医薬の使用 |
| CN110446712B (zh) * | 2017-04-07 | 2021-09-14 | 南京明德新药研发有限公司 | 作为A2A受体抑制剂的[1,2,4]三唑并[1,5-c]嘧啶衍生物 |
| CN109535161B (zh) * | 2017-09-22 | 2021-09-03 | 江苏恒瑞医药股份有限公司 | 三唑并嘧啶类衍生物、其制备方法及其在医药上的应用 |
| CN112384515A (zh) * | 2018-02-27 | 2021-02-19 | 因赛特公司 | 作为a2a/a2b抑制剂的咪唑并嘧啶和三唑并嘧啶 |
| PL3766884T3 (pl) * | 2018-04-28 | 2022-07-18 | Medshine Discovery Inc. | Postać krystaliczna i rodzaj soli związku triazolopirymidynowego oraz sposób jej wytwarzania |
| AR116315A1 (es) * | 2018-09-12 | 2021-04-21 | Dizal Jiangsu Pharmaceutical Co Ltd | Compuestos de triazolo-pirimidina y usos de los mismos |
-
2019
- 2019-09-11 AR ARP190102589A patent/AR116315A1/es unknown
- 2019-09-11 TW TW108132759A patent/TWI820209B/zh active
- 2019-09-12 MX MX2021002998A patent/MX2021002998A/es unknown
- 2019-09-12 WO PCT/CN2019/105591 patent/WO2020052631A1/en unknown
- 2019-09-12 AU AU2019340767A patent/AU2019340767A1/en active Pending
- 2019-09-12 CN CN202010656938.4A patent/CN111635408B/zh active Active
- 2019-09-12 JP JP2021513827A patent/JP2022500402A/ja active Pending
- 2019-09-12 EP EP19859380.8A patent/EP3849983A4/en active Pending
- 2019-09-12 BR BR112021004774-3A patent/BR112021004774A2/pt unknown
- 2019-09-12 CN CN202010657655.1A patent/CN112279852B/zh active Active
- 2019-09-12 CN CN201980006436.2A patent/CN111601809A/zh active Pending
- 2019-09-12 KR KR1020217010809A patent/KR20210075996A/ko unknown
- 2019-09-12 CA CA3111869A patent/CA3111869A1/en active Pending
-
2020
- 2020-06-24 US US16/910,334 patent/US10858365B2/en active Active
- 2020-09-22 US US17/027,740 patent/US11629147B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11591336B2 (en) | Substituted pyrazolo[3,4-b]pyrazines as SHP2 phosphatase inhibitors | |
| CA2984259C (en) | Combinations of inhibitors of irak4 with inhibitors of btk | |
| RU2424242C2 (ru) | Азолопиримидины в качестве ингибиторов активности каннабиноидного рецептора 1 | |
| JP2013508404A5 (ko) | ||
| JP2019504821A5 (ko) | ||
| JP2016500073A5 (ko) | ||
| JP2012532931A5 (ko) | ||
| JP2019530695A5 (ko) | ||
| IL187690A (en) | Derivatives 1, 2, 4 - Triazolo - 1, 6 - Naphthiridines as inhibitors of AKT activity for use in the preparation of drugs for the treatment of cancer | |
| JP2013523884A5 (ko) | ||
| JP2016500671A5 (ko) | ||
| KR20210075996A (ko) | 트리아졸로-피리미딘 화합물 및 그의 용도 | |
| RU2017105296A (ru) | Новые соединения | |
| JP2016522246A5 (ko) | ||
| JP2012525395A5 (ko) | ||
| CA2570987A1 (en) | Novel alkynyl derivatives as modulators of metabotropic glutamate receptors | |
| RU2012130436A (ru) | Новое антитромботическое средство | |
| JPWO2020052631A5 (ko) | ||
| JP2017500364A5 (ko) | ||
| JP2018536671A5 (ko) | ||
| JP2016504290A5 (ko) | ||
| JP2016507551A5 (ko) | ||
| TW201927779A (zh) | 作為ＰＤＥ１抑制劑的１Ｈ-吡唑并[４，３-ｂ]吡啶 | |
| EP2594270A2 (en) | The use of sGC stimulators, sGC activators, alone and combinations with PDE5 inhibitors for the treatment of systemic sclerosis (SSc) | |
| WO2017157792A1 (en) | Combinations of copanlisib |